» Articles » PMID: 24198402

Human Herpesvirus 8 Interleukin-6 Contributes to Primary Effusion Lymphoma Cell Viability Via Suppression of Proapoptotic Cathepsin D, a Cointeraction Partner of Vitamin K Epoxide Reductase Complex Subunit 1 Variant 2

Overview
Journal J Virol
Date 2013 Nov 8
PMID 24198402
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Human herpesvirus 8 (HHV-8) interleukin-6 (vIL-6) promotes cell proliferation and survival and is proangiogenic, implicating it as a contributor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease. Although predominantly lytically expressed, vIL-6 is also produced at low, functional levels during latency in PEL cells. Unlike other IL-6 cytokines, vIL-6 is secreted very inefficiently and localizes in the endoplasmic reticulum (ER). ER-localized vIL-6 supports PEL cell proliferation and survival, mediated in part through its interaction with the largely uncharacterized ER-resident protein vitamin K epoxide reductase complex subunit 1 variant 2 (VKORC1v2). Here, we report that the ER-transiting and functionally mitogenic secreted proenzyme (pCatD) form of cathepsin D (mature CatD), a proapoptotic lysosomal aspartate protease, is an interaction partner of VKORC1v2 and that vIL-6 promotes this interaction. Depletion of vIL-6 in PEL cells increased levels of the catalytically active, proteolytically cleaved form of CatD, corresponding with decreased PEL cell viability. Ectopic expression of CatD in PEL cells induced apoptosis, suggesting that CatD suppression by vIL-6 is biologically significant. In the context of high-density culture or reactivation of HHV-8 lytic replication in PEL cells, CatD depletion substantially reduced stress-induced apoptosis and increased virus production. In contrast, CatD overexpression, vIL-6 depletion, and peptide-mediated disruption of vIL-6-VKORC1v2 interaction inhibited replication and cell survival. Combined, our data identify pCatD as an interaction partner of VKORC1v2, demonstrate a role of vIL-6 in CatD suppression via VKORC1v2 in PEL cells, and identify a biologically significant mechanism of vIL-6 prosurvival and proreplication activities via VKORC1v2.

Citing Articles

Today's Kaposi sarcoma is not the same as it was 40 years ago, or is it?.

Damania B, Dittmer D J Med Virol. 2023; 95(5):e28773.

PMID: 37212317 PMC: 10266714. DOI: 10.1002/jmv.28773.


Kaposi's Sarcoma-associated Herpesvirus microRNA mutants modulate cancer hallmark phenotypic differences in human endothelial cells.

Gay L, Stribling D, Turner P, Renne R J Virol. 2021; 95(10).

PMID: 33568509 PMC: 8092706. DOI: 10.1128/JVI.02022-20.


Lymphotropic Viruses: Chronic Inflammation and Induction of Cancers.

Harhaj E, Shembade N Biology (Basel). 2020; 9(11).

PMID: 33182552 PMC: 7697807. DOI: 10.3390/biology9110390.


Genetic Analyses of Contributions of Viral Interleukin-6 Interactions and Signaling to Human Herpesvirus 8 Productive Replication.

Li Q, Xiang Q, Chen D, Nicholas J J Virol. 2020; 94(19).

PMID: 32669340 PMC: 7495386. DOI: 10.1128/JVI.00909-20.


KSHV: Immune Modulation and Immunotherapy.

Broussard G, Damania B Front Immunol. 2020; 10:3084.

PMID: 32117196 PMC: 7025529. DOI: 10.3389/fimmu.2019.03084.


References
1.
Uldrick T, Polizzotto M, Yarchoan R . Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 2012; 24(5):495-505. PMC: 6322210. DOI: 10.1097/CCO.0b013e328355e0f3. View

2.
Laurent-Matha V, Maruani-Herrmann S, Prebois C, Beaujouin M, Glondu M, Noel A . Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J Cell Biol. 2005; 168(3):489-99. PMC: 2171724. DOI: 10.1083/jcb.200403078. View

3.
Chen D, Cousins E, Sandford G, Nicholas J . Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1. J Virol. 2011; 86(3):1577-88. PMC: 3264350. DOI: 10.1128/JVI.05782-11. View

4.
Wan X, Wang H, Nicholas J . Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol. 1999; 73(10):8268-78. PMC: 112844. DOI: 10.1128/JVI.73.10.8268-8278.1999. View

5.
Bazzett L, Watkins C, Gercel-Taylor C, Taylor D . Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol. 1999; 74(2):181-7. DOI: 10.1006/gyno.1999.5426. View